Drug Profile
Adapalene/benzoyl peroxide/clindamycin phosphate - Bausch Health Companies
Alternative Names: Benzoyl peroxide/clindamycin phosphate/adapalene; Cabtreo; Clindamycin phosphate/adapalene/benzoyl peroxide; IDP 126Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class Adamantanes; Anti-inflammatories; Antiacnes; Antibacterials; Benzoic acids; Keratolytics; Lincosamides; Naphthalenes; Oxidants; Pyrrolidines; Retinoids; Small molecules
- Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acne vulgaris
Most Recent Events
- 27 Feb 2024 Launched for Acne vulgaris in USA (Topical) in the first quarter of 2024
- 20 Oct 2023 Bausch Health Companies announces intention to launch Adapalene/benzoyl peroxide/clindamycin phosphate (In adolescents, In adults) in USA (Topical, Gel) in Acne vulgaris in Q1 2024
- 20 Oct 2023 Registered for Acne vulgaris (In adolescents, In adults) in USA (Topical)